Skip to Content

IMATINIB DEVATIS 400 MG FILM-COATED TABLETS

Active substance(s): IMATINIB MESILATE

View full screen / Print PDF » Download PDF ⇩
Transcript
Package leaflet: Information for the user
Imatinib 400 mg film-coated tablets
Imatinib mesilate
Read all of this leaflet carefully before you start taking this medicine because it contains
important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them,
even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible
side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Imatinib is and what it is used for
2. What you need to know before you take Imatinib
3. How to take Imatinib
4. Possible side effects
5. How to store Imatinib
6. Contents of the pack and other information

1. What Imatinib is and what it is used for
Imatinib is a medicine containing an active substance called imatinib. This medicine works by
inhibiting the growth of abnormal cells in the diseases listed below. These include some types of
cancer.
Imatinib is a treatment for adults and children for:
-

-

Chronic myeloid leukaemia (CML).
Leukaemia is a cancer of white blood cells. These white cells usually help the body to fight
infection. Chronic myeloid leukaemia is a form of leukaemia in which certain abnormal white
cells (named myeloid cells) start growing out of control.
In adult patients Imatinib is used to treat a late stage of chronic myeloid leukaemia called „blast
crisis“. In children and adolescents however it may be used to treat all stages of the illness.
Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph-positive ALL).
Leukaemia is a cancer of white blood cells. These white cells usually help the body to fight
infection. Acute lymphoblastic leukaemia is a form of leukaemia in which certain abnormal white
cells (named lymphoblasts) start growing out of control. Imatinib inhibits the growth of these
cells.

Imatinib is also a treatment for adults for:
-

-

Myelodysplastic/myeloproliferative diseases (MDS/MPD).
These are a group of blood diseases in which some blood cells start growing out of control.
Imatinib inhibits the growth of these cells in a certain subtype of these diseases.
Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL).
These are blood diseases in which some blood cells (named eosinophils) start growing out of
control. Imatinib inhibits the growth of these cells in a certain subtype of these diseases.

-

Dermatofibrosarcoma protuberans (DFSP).
DFSP is a cancer of the tissue beneath the skin in which some cells start growing out of control.
Imatinib inhibits the growth of these cells.

In the rest of this leaflet, we will use the abbreviations when talking about these diseases.
If you have any questions about how Imatinib works or why this medicine has been prescribed for
you, ask your doctor.

2. What you need to know before you take Imatinib
Imatinib will only be prescribed to you by a doctor with experience in medicines to treat blood cancers
or solid tumours.
Follow all your doctor’s instructions carefully, even if they differ from the general information
contained in this leaflet.

Do not take Imatinib:
- if you are allergic to imatinib or any of the other ingredients of this medicine (listed in section 6).
If this applies to you, tell your doctor without taking Imatinib.
If you think you may be allergic but are not sure, ask your doctor for advice.
Warnings and precautions
Talk to your doctor before taking Imatinib:
- if you have or have ever had a liver, kidney or heart problem.
- if you have ever had or might now have a hepatitis B infection. This is because Imatinib could
cause hepatitis B to become active again, which can be fatal in some cases. Patients will be
carefully checked by their doctor for signs of this infection before treatment is started.
- if you are taking the medicine levothyroxine because your thyroid has been removed.
If any of these apply to you, tell your doctor before taking Imatinib.
During treatment with Imatinib, tell your doctor straight away if you put on weight very quickly.
Imatinib may cause your body to retain water (severe fluid retention).
While you are taking Imatinib, your doctor will regularly check whether the medicine is working. You
will also have blood tests and be weighed regularly.
Children and adolescents
Imatinib is also a treatment for children with CML. There is no experience in children with CML
below 2 years of age. There is limited experience in children with Ph-positive ALL and very limited
experience in children with MDS/MPD, DFSP, GIST and HES/CEL.
Some children and adolescents taking Imatinib may have slower than normal growth. The doctor will
monitor the growth at regular visits.
Other medicines and Imatinib
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other
medicines, including medicines obtained without a prescription (such as paracetamol) and including
herbal medicines (such as St. John’s Wort). Some medicines can interfere with the effect of Imatinib
when taken together. They may increase or decrease the effect of Imatinib, either leading to increased
side effects or making Imatinib less effective. Imatinib may do the same to some other medicines.

Tell your doctor if you are using medicines that prevent the formation of blood clots.
Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask
your doctor for advice before taking this medicine.
Imatinib is not recommended during pregnancy unless clearly necessary as it may harm your baby.
Your doctor will discuss with you the possible risks of taking Imatinib during pregnancy.
- Women who might become pregnant are advised to use effective contraception during treatment.
- Do not breast-feed during the treatment with Imatinib.
- Patients who are concerned about their fertility while taking Imatinib are advised to consult with
their doctor.
Driving and using machines
You may feel dizzy or drowsy or get blurred vision while taking this medicine. If this happens, do not
drive or use any tools or machines until you are feeling well again.

3. How to take Imatinib
Your doctor has prescribed Imatinib because you suffer from a serious condition. Imatinib can help
you to fight this condition.
Always take this medicine exactly as your doctor or pharmacist has told you. It is important that you
do this as long as your doctor or pharmacist tells you to. Check with your doctor or pharmacist if you
are not sure.
Do not stop taking Imatinib unless your doctor tells you to. If you are not able to take the medicine as
your doctor prescribed or you feel you do not need it anymore, contact your doctor straight away.
How much Imatinib to take
Use in adults
Your doctor will tell you exactly how many tablets of Imatinib to take.
-

If you are being treated for CML:
The usual starting dose is 600 mg, to be taken once a day.

Your doctor may prescribe a higher or lower dose depending on how you respond to the treatment. If
your daily dose is 800 mg (2 tablets), you should take 1 tablet in the morning and 1 tablet in the
evening.
-

If you are being treated for Ph-positive ALL:
The starting dose is 600 mg to be taken once a day.

-

If you are being treated for MDS/MPD:
The starting dose is 400 mg to be taken as 1 tablet once a day.

-

If you are being treated for HES/CEL:
The starting dose is 100 mg, to be taken as one tablet once a day. Your doctor may decide to
increase the dose to 400 mg, to be taken as 1 tablet once a day, depending on how you respond to
treatment.

-

If you are being treated for DFSP:
The dose is 800 mg per day 2 tablets, to be taken as 1 tablet in the morning and 1 tablet in the
evening.

Use in children and adolescents
The doctor will tell you how many tablets of Imatinib to give to your child. The amount of Imatinib
given will depend on your child’s condition, body weight and height. The total daily dose in children
must not exceed 800 mg. The treatment can either be given to your child as a once-daily dose or
alternatively the daily dose can be split into two administrations (half in the morning and half in the
evening).

When and how to take Imatinib
- Take Imatinib with a meal. This will help protect you from stomach problems when taking
Imatinib.
- Swallow the tablets whole with a large glass of water.
If you are unable to swallow the tablets, you can dissolve them in a glass of still water or apple juice:
• Use about 200 ml for each 400 mg tablet.
• Stir with a spoon until the tablets have completely dissolved.
• Once the tablet has dissolved, drink everything in the glass straight away. Traces of the dissolved
tablets may be left behind in the glass.
How long to take Imatinib
Keep taking Imatinib every day for as long as your doctor tells you.
If you take more Imatinib than you should
If you have accidentally taken too many tablets, talk to your doctor straight away. You may require
medical attention. Take the medicine pack with you.
If you forget to take Imatinib
- If you forget a dose, take it as soon as you remember. However if it is nearly time for the next
dose, skip the missed dose.
- Then continue with your normal schedule.
- Do not take a double dose to make up a forgotten dose.

4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. They are
usually mild to moderate.
Some side effects may be serious. Tell your doctor straight away if you get any of the following:
Very common (may affect more than 1 in 10 people) or common (may affect up to 1 in 10 people):
• Rapid weight gain. Imatinib may cause your body to retain water (severe fluid retention).
• Signs of infection such as fever, severe chills, sore throat or mouth ulcers. Imatinib can reduce the
number of white blood cells, so you might get infections more easily.
• Unexpected bleeding or bruising (when you have not hurt yourself).
Uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people):
• Chest pain, irregular heart rhythm (signs of heart problems).
• Cough, having difficulty in breathing or painful breathing (signs of lung problems).
• Feeling light-headed, dizzy or fainting (signs of low blood pressure).




















Feeling sick (nausea), with loss of appetite, dark-coloured urine, yellow skin or eyes (signs of liver
problems).
Rash, red skin with blisters on the lips, eyes, skin or mouth, peeling skin, fever, raised red or
purple skin patches, itching, burning sensation, pustular eruption (signs of skin problems).
Severe abdominal pain, blood in your vomit, stools or urine, black stools (signs of gastrointestinal
disorders).
Severely decreased urine output, feeling thirsty (signs of kidney problems).
Feeling sick (nausea) with diarrhoea and vomiting, abdominal pain or fever (signs of bowel
problems).
Severe headache, weakness or paralysis of limbs or face, difficulty speaking, sudden loss of
consciousness (signs of nervous system problems such as bleeding or swelling in skull/brain).
Pale skin, feeling tired and breathlessness and having dark urine (signs of low levels of red blood
cells).
Eye pain or deterioration in vision, bleeding in the eyes.
Pain in your hips or difficulty walking.
Numb or cold toes and fingers (signs of Raynaud’s syndrome).
Sudden swelling and redness of the skin (signs of a skin infection called cellulites).
Difficulty hearing.
Muscle weakness and spasms with an abnormal heart rhythm (signs of changes in the amount of
potassium in your blood).
Bruising.
Stomach pain with feeling sick (nausea).
Muscle spasms with a fever, red-brown urine, pain or weakness in your muscles (signs of muscle
problems).
Pelvic pain sometimes with nausea and vomiting, with unexpected vaginal bleeding, feeling dizzy
or fainting due to low blood pressure (signs of problems with your ovaries or womb).
Nausea, shortness of breath, irregular heartbeat, clouding of urine, tiredness and/or joint
discomfort associated with abnormal laboratory test results (eg. high potassium, uric acid and
calcium levels and low phosphorous levels in the blood).

Not known (frequency cannot be estimated from the available data):
• Combination of a widespread severe rash, feeling sick, fever, high level of certain white blood
cells or yellow skin or eyes (signs of jaundice) with breathlessness, chest pain/discomfort, severely
decreased urine output and feeling thirsty etc. (signs of a treatment-related allergic reaction.
• Chronic renal failure.
• Recurrence (reactivation) of Hepatitis B infection when you have had hepatitis B in the past (a
liver infection).
If you get any of the above, tell your doctor straight away.
Other side effects may include:
Very common (may affect more than 1 in 10 people):
• Headache or feeling tired.
• Feeling sick (nausea), being sick (vomiting), diarrhoea or indigestion.
• Rash.
• Muscle cramps or joint, muscle or bone pain.
• Swelling such as round your ankles or puffy eyes.
• Weight gain.
If any of these affects you severely, tell your doctor.
Common (may affect up to 1 in 10 people):
• Anorexia, weight loss or a disturbed sense of taste.
• Feeling dizzy or weak.




Difficulty in sleeping (insomnia).
Discharge from the eye with itching, redness and swelling (conjunctivitis), watery eyes or having
blurred vision.
• Nose bleeds.
• Pain or swelling in your abdomen, flatulence, heartburn or constipation.
• Itching.
• Unusual hair loss or thinning.
• Numbness of the hands or feet.
• Mouth ulcers.
• Joint pain with swelling.
• Dry mouth, dry skin or dry eye.
• Decreased or increased skin sensitivity.
• Hot flushes, chills or night sweats.
If any of these affects you severely, tell your doctor.
Not known (frequency cannot be estimated from the available data):
• Reddening and/or swelling on the palms of the hands and soles of the feet which may be
accompanied by tingling sensation and burning pain.
• Slowing of growth in children and adolescents.
If any of these affects you severely, tell your doctor.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects
not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme on the
Website: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more
information on the safety of this medicine.

5. How to store Imatinib






Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry
date refers to the last day of that month.
This medicinal product does not require any special storage conditions.
Do not use any pack that is damaged or shows signs of tampering.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how
to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information
What Imatinib contains
The active substance is imatinib mesilate.
Each tablet of Imatinib 400 mg contains 400 mg imatinib (as mesilate).
The other ingredients microcrystalline cellulose, hypromellose, crospovidone, magnesium
stearate and anhydrous colloidal silica.
The tablet coating is made of poly(vinyl alcohol), macrogol, yellow iron oxide (E172), red iron
oxide (E172), talc and titanium dioxide (E171).
What Imatinib looks like and contents of the pack
Imatinib 400 mg film-coated tablets are dark yellow to brownish-orange coloured, capsule-shaped,
biconvex film-coated tablets with dimensions 21.3 mm x 9.6 mm approximately.

They are supplied in packs containing 10, 30, 60 and 90 film-coated tablets
Marketing Authorisation Holder and Manufacturer
Devatis GmbH
Spitalstr. 22
79539 Lörrach
Germany
This medicinal product is authorised in the Member States of the EEA under the following
names:
Netherlands
Belgium
Germany
Portugal
United Kingdom

Imatinib Devatis
Imatinib Devatis
Imatinib Devatis
Imatinib Devatis
Imatinib Devatis

This leaflet was approved in 05/2016

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide